

Vincent Launay-Vacher

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5132457/vincent-launay-vacher-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

5,070
citations

37
h-index

67
g-index

201
ext. papers

5,882
ext. citations

4.3
avg, IF

5.38
L-index

#	Paper	IF	Citations
154	Antiviral drug-induced nephrotoxicity. <i>American Journal of Kidney Diseases</i> , 2005 , 45, 804-17	7.4	299
153	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. <i>Cancer</i> , 2007 , 110, 1376-84	6.4	293
152	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , 2017 , 45, 160-169	4.6	220
151	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , 2007 , 43, 14-34	7.5	198
150	Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 903-9	3.5	196
149	Drug-induced Fanconi's syndrome. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 292-309	7.4	170
148	Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 743-6	4.3	164
147	Renal safety of tenofovir in HIV treatment-experienced patients. <i>Aids</i> , 2004 , 18, 1074-6	3.5	133
146	Cancer and renal insufficiency results of the BIRMA study. <i>British Journal of Cancer</i> , 2010 , 103, 1815-21	8.7	120
145	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. <i>Kidney International</i> , 2004 , 66, 1153-8	9.9	120
144	Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Annals of Oncology</i> , 2010 , 21, 1395-1403	10.3	112
143	Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. <i>Annals of Oncology</i> , 2007 , 18, 1314-21	10.3	110
142	Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. <i>Radiology</i> , 2009 , 250, 618-28	20.5	100
141	Gemcitabine-induced thrombotic microangiopathy: a systematic review. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 3038-45	4.3	95
140	Renal tubular drug transporters. <i>Nephron Physiology</i> , 2006 , 103, p97-106		88
139	Abnormal blood pressure circadian rhythm: a target organ damage?. <i>International Journal of Cardiology</i> , 2006 , 107, 343-9	3.2	81
138	Hypertension and proteinuria: a class-effect of antiangiogenic therapies. <i>Anti-Cancer Drugs</i> , 2009 , 20, 81-2	2.4	80

137	Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2852-9	4.3	64
136	Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. <i>Liver Transplantation</i> , 2009 , 15, 1083-91	4.5	62
135	Medication misuse in hospitalized patients with renal impairment. <i>International Journal for Quality in Health Care</i> , 2003 , 15, 331-5	1.9	60
134	Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. <i>Rheumatology</i> , 2008 , 47, 350-4	3.9	59
133	Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. <i>Seminars in Nephrology</i> , 2010 , 30, 548-56	4.8	57
132	Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 315-329	4.5	56
131	Antiretroviral and immunosuppressive drug-drug interactions: an update. <i>Kidney International</i> , 2004 , 66, 532-41	9.9	55
130	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <i>Annals of Oncology</i> , 2015 , 26, 1677-84	10.3	52
129	Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrologique Systémique study. <i>Investigative Radiology</i> , 2014 , 49, 109-15	10.1	52
128	Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. <i>International Journal of Cardiology</i> , 2005 , 101, 9-17	3.2	52
127	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2016 , 9, 245-51	4.5	50
126	Clinical review: use of vancomycin in haemodialysis patients. <i>Critical Care</i> , 2002 , 6, 313-6	10.8	50
125	Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. <i>Annals of Oncology</i> , 2013 , 24, 501-507	10.3	47
124	Importance of monitoring renal function in patients with cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 235-40	14.4	45
123	Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. <i>Journal of Pain</i> , 2005 , 6, 137-48	5.2	45
122	Anemia and diabetes. <i>American Journal of Nephrology</i> , 2004 , 24, 522-6	4.6	42
121	Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?. <i>Annals of Oncology</i> , 2009 , 20, 600-1	10.3	40
120	Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. <i>Cancer</i> , 2014 , 120, 2158-63	6.4	38

119	Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. <i>European Journal of Radiology</i> , 2010 , 73, 357-9	4.7	37
118	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 745-53	4.4	37
117	Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. <i>Targeted Oncology</i> , 2015 , 10, 199-213	5	36
116	Ear and kidney syndromes: molecular versus clinical approach. <i>Kidney International</i> , 2004 , 65, 369-85	9.9	36
115	An appraisal of antiretroviral drugs in hemodialysis. <i>Kidney International</i> , 2001 , 60, 821-30	9.9	36
114	Lung cancer and renal insufficiency: prevalence and anticancer drug issues. <i>Lung</i> , 2009 , 187, 69-74	2.9	34
113	Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 124-33	7	34
112	Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. <i>Clinical Infectious Diseases</i> , 2007 , 45, 779-84	11.6	34
111	Eye and kidney: from clinical findings to genetic explanations. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 516-29	12.7	34
110	Fanconi syndrome associated with didanosine therapy. <i>Aids</i> , 2005 , 19, 844-5	3.5	33
109	Onco-nephrology: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 869-83	7.4	31
108	Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 503-7	6.1	31
107	Viral load and HIV-associated nephropathy. <i>New England Journal of Medicine</i> , 2005 , 353, 1072-4	59.2	31
106	Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. <i>Medical Science Monitor</i> , 2004 , 10, CR209-12	3.2	31
105	Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. <i>Liver International</i> , 2015 , 35, 148-55	7.9	30
104	Renal insufficiency and cancer treatments. <i>ESMO Open</i> , 2016 , 1, e000091	6	29
103	Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2004 , 77, 319	7.1	28
102	Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. <i>American Journal of Nephrology</i> , 2001 , 21, 162-4	4.6	28

101	Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?. <i>AIDS Reviews</i> , 2016 , 18, 184-192	1.5	28
100	Effect of N-acetylcysteine on serum creatinine level. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1514-1517	4.5	27
99	Drug-induced diabetes mellitus. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 1097-109	4.1	26
98	Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. <i>Nephron</i> , 2001 , 89, 62-7	3.3	26
97	Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis. <i>American Journal of Medicine</i> , 2002 , 113, 164-6	2.4	26
96	Opening an onconeurology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1503-1510	4.3	26
95	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019 , 96, 555-567	9.9	25
94	Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. <i>Supportive Care in Cancer</i> , 2012 , 20, 3033-42	3.9	23
93	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , 2018 , 19, e317-e326	21.7	23
92	Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 221-35	6.2	21
91	Thrombocytopenia induced by nicotinamide in hemodialysis patients. <i>Kidney International</i> , 2005 , 68, 2911-2	9.9	21
90	Drug-induced glomerulopathies. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 95-106	4.1	20
89	Pharmacokinetics of tenofovir in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 1931-3	4.3	20
88	Baclofen neurotoxicity [correction of unerotoxicity] in a chronic haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 715-6	4.3	20
87	Gabapentin neurotoxicity in a chronic haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 2112-3	4.3	20
86	Drug management of prostate cancer: prevalence and consequences of renal insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E83-9	3.3	19
85	Assessing residents' prescribing behavior in renal impairment. <i>International Journal for Quality in Health Care</i> , 2003 , 15, 235-40	1.9	18
84	Topiramate-induced renal tubular acidosis. <i>American Journal of Medicine</i> , 2004 , 116, 281-2	2.4	17

83	Acute pancreatitis induced by isoniazid. <i>American Journal of Gastroenterology</i> , 2001 , 96, 3208-9	0.7	16
82	Pharmacokinetics of tramadol in a hemodialysis patient. <i>Nephron</i> , 2002 , 92, 755-6	3.3	16
81	Pharmacokinetic of nevirapine in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 192-3	4.3	15
80	Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 492-4	2.8	14
79	Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 3606-8	4.3	14
78	An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1361-7	3.5	13
77	Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4223-5	2.2	13
76	Evaluation of current practice: management of chemotherapy-related toxicities. <i>Anti-Cancer Drugs</i> , 2011 , 22, 919-25	2.4	12
75	Oculorenal manifestations in systemic autoimmune diseases. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 209-22	7.4	12
74	Lymphopenia in Wegener's granulomatosis. A new clinical activity index?. <i>Nephron</i> , 2002 , 92, 466-71	3.3	12
73	Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 852-3	4.3	11
72	Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis. <i>Aids</i> , 2000 , 14, 618-9	3.5	11
71	ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. <i>Aids</i> , 2001 , 15, 662-4	3.5	10
70	A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 129, 79-98	7	10
69	Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study. <i>Transplant International</i> , 2014 , 27, 931-8	3	9
68	Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 362-3	6.1	9
67	FHD: an index to evaluate drug elimination by hemodialysis. <i>American Journal of Nephrology</i> , 2005 , 25, 342-51	4.6	8
66	Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient. <i>Nephron</i> , 2001 , 87, 91-2	3.3	8

65	Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient. <i>Nephron</i> , 2001 , 87, 186-7	3.3	8
64	Antiretroviral drugs and the kidney: dosage adjustment and renal tolerance. <i>Current Pharmaceutical Design</i> , 2004 , 10, 4071-9	3.3	8
63	Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1363-7	3.5	7
62	Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. <i>Aids</i> , 1999 , 13, 1989	3.5	7
61	Anticancer Drugs in End-Stage Kidney Disease Patients. <i>Seminars in Dialysis</i> , 2015 , 28, 413-6	2.5	6
60	Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis. <i>Kidney International</i> , 2003 , 64, 2324	9.9	6
59	Dosage of lamivudine in a haemodialysis patient. <i>Nephron</i> , 2000 , 86, 553	3.3	6
58	Malaria prophylaxis in patients with renal impairment: a review. <i>Drug Safety</i> , 2013 , 36, 83-91	5.1	5
57	European Society of Clinical Pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargon. <i>International Journal of Clinical Pharmacy</i> , 2012 , 34, 263-8	2.3	5
56	Thalidomide for the nephrologist. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 2011-2	4.3	5
55	Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 531-2	4.3	5
54	Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2428	2.2	5
53	Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1522	5.3	4
52	New therapies for hepatitis C: considerations in patients with renal impairment. <i>Drugs</i> , 2014 , 74, 1307-1321	2.1	4
51	Letter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. <i>International Journal of Gynecological Cancer</i> , 2007 , 17, 1340-1; author reply 1342	3.5	4
50	Using the right MDRD equation. <i>Kidney International</i> , 2004 , 66, 2089; author reply 2089-90	9.9	4
49	Overall survival in solid tumor patients with abnormal renal function or renal insufficiency.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1589-1589	2.2	4
48	Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice. <i>Médecine Et Maladies Infectieuses</i> , 2020 , 50, 323-331	4	4

47	Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 617-623	5.5	3
46	Néphrotoxicité des médicaments. <i>Revue Francophone Des Laboratoires</i> , 2013 , 2013, 75-82	0	3
45	Mise à jour des recommandations de la MASCC et de l'ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de Pérouse. <i>Oncologie</i> , 2012 , 14, 329-342	1	3
44	Why is a shrunken bladder and a nephrotic kidney an expression of the same disease?. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 3193-5	4.3	3
43	Epidemiology of microscopic polyarteritis: a 16-year study. <i>Kidney International</i> , 2004 , 65, 741	9.9	3
42	Results of the MARS study on the management of antiangiogenics: renal safety in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5567-5567	2.2	3
41	Fanconi and inappropriate secretion of antidiuretic hormone syndromes secondary to venlafaxine therapy. <i>Nephron</i> , 2002 , 92, 944-6	3.3	2
40	Renal function and venous thromboembolic diseases. <i>Journal Des Maladies Vasculaires</i> , 2016 , 41, 389-395		2
39	Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	1
38	Médicaments et insuffisance rénale. <i>Actualités Pharmaceutiques</i> , 2018 , 57, 33-36	0	1
37	Colony stimulating factors (CSF) biosimilars. Progress?. <i>Targeted Oncology</i> , 2012 , 7 Suppl 1, S17-24	5	1
36	Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. <i>Supportive Care in Cancer</i> , 2013 , 21, 2743-8	3.9	1
35	Toxicité des chélates de gadolinium chez le patient insuffisant rénal. <i>Sang Thrombose Vaisseaux</i> , 2010 , 22, 90-95	3	1
34	Lymphadenopathy and proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 739-41	4.3	1
33	Immunosuppressive and calcimimetic drug-drug interactions. <i>Kidney International</i> , 2005 , 68, 1903-4	9.9	1
32	Antiretroviral drugs and the kidney: further precisions. <i>Kidney International</i> , 2005 , 68, 409	9.9	1
31	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <i>Journal of Onco-Nephrology</i> , 2018 , 2, 37-49	0.2	1
30	Anticoagulants in frail patients. Seven situations at risk. <i>JMV-Journal De Medecine Vasculaire</i> , 2018 , 43, 302-309	0.6	1

29	MMoPraticVDHA: guide de prescription pour les voies digestives hautes altEs. <i>Oncologie</i> , 2011 , 13, 116-121	1	0
28	Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2548-2548	2.2	0
27	Adaptations posologiques chez le patient greffEal. <i>Actualites Pharmaceutiques</i> , 2019 , 58, 31-32	0	
26	Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 653-5	3.5	
25	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , 2017 , 1, 213-219	0.2	
24	Course of chronic kidney disease in French patients. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 74-78	4.5	
23	Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. <i>Supportive Care in Cancer</i> , 2016 , 24, 3347-51	3.9	
22	Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists. <i>Annals of Oncology</i> , 2016 , 27, 752	10.3	
21	Pulmonary hypertension: use of oral drugs in patients with renal insufficiency. <i>Clinical Drug Investigation</i> , 2013 , 33, 65-9	3.2	
20	MMoPraticVDHA*: douleurs et soins de support: guide de prescription pour les voies digestives hautes altEs. <i>Douleur Et Analgesie</i> , 2011 , 24, 56-60	0.2	
19	Prescrire les bisphosphonates IV pour la prise en charge des mEastes osseuses chez le patient insuffisant rEal. <i>ProgrE En Urologie - FMC</i> , 2008 , 18, F19-F23	0	
18	Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply. <i>Rheumatology</i> , 2008 , 47, 1259-1260	3.9	
17	Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer. <i>CKJ: Clinical Kidney Journal</i> , 2008 , 1, 196-7	4.5	
16	Hemodialysis and ADAMTS-13. <i>Blood Purification</i> , 2004 , 22, 480	3.1	
15	Antiretroviral drugs and the kidney: Further precisions. <i>Kidney International</i> , 2005 , 68, 409	9.9	
14	Hepatitis C infection. <i>Kidney International</i> , 2005 , 68, 2402	9.9	
13	E.F.P.--European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe. <i>International Journal of Clinical Pharmacy</i> , 2005 , 27, 278		
12	Hepatitis C infection and proteinuria. <i>Kidney International</i> , 2005 , 68, 2402	9.9	

- 11 AUCtox: A new method to evaluate the safety of anticancer drugs.. *Journal of Clinical Oncology*, **2018**, 36, 2534-2534 2.2
- 10 AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 290-290 2.2
- 9 Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC) A real-life ambispective study.. *Journal of Clinical Oncology*, **2019**, 37, 5540-5540 2.2
- 8 Leaning upon International Directives for Optimization: Anemia Results of the French LIDO anemia survey.. *Journal of Clinical Oncology*, **2015**, 33, e20739-e20739 2.2
- 7 Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria.. *Journal of Clinical Oncology*, **2015**, 33, e16056-e16056 2.2
- 6 Leaning upon international directives for optimization: Anemia Results of the French Lido anemia-2 Survey.. *Journal of Clinical Oncology*, **2015**, 33, 180-180 2.2
- 5 Preliminary results of the VENUS study: Bevacizumab efficacy and safety in recurrent, platinum-sensitive ovarian cancer A real-life ambispective study.. *Journal of Clinical Oncology*, **2017**, 35, e17093-e17093 2.2
- 4 Management of antiangiogenics Renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. *Journal of Clinical Oncology*, **2012**, 30, 5067-5067 2.2
- 3 Management of antiangiogenics Renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. *Journal of Clinical Oncology*, **2012**, 30, 1095-1095 2.2
- 2 Results of the MARS study on the management of antiangiogenics Renovascular safety in colorectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 466-466 2.2
- 1 Results of the MARS study on the management of antiangiogenics Renovascular safety in renal cell carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 394-394 2.2